Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 2,201–2,300 of 2,576
Identification of novel regulators involved in AD pathogenesis using the CRISPR-Cas9 system
Tomizawa, I., Chiu, Y., Hori, Y., & Tomita, T. (2022) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22081 · Cited by 1
Functional data classification using the rotation forest method combined with the patch selection
Chang, J. (2023) · Communications in Statistics - Simulation and Computation · doi:10.1080/03610918.2023.2205619 · Cited by 2
“All but a handful of the more than 200 EO-FAD mutations in APP, PSEN1 and PSEN2 lead to a common molecular phenotype: an increase in the ratio of A b 42 : A b 40 (Scheuner et al. 1996; Tanzi and Bertram 2005; Sherrington et al. 1995).”
BackgroundWang, Z., Niu, L., & Riaz, S. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-34229-5_11 · Cited by 1
Jáuregui, G. V., & Parpura, V. (2025) · Ageing & Longevity · doi:10.47855/jal9020-2025-2-3 · Cited by 2
Wang, L., Park, S., Choi, J. H., Lee, C. Y., Eom, K., & Kwon, T. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2475221 · Cited by 1
“The concentration ratio of A b 42 to A b 40 is related to the familial form of AD (Scheuner et al., 1996), as this ratio determines the fibrillation, toxicity, and pathological distribution of A b .”
Inducible Pluripotent Stem Cells In Autism Spectrum Disorders
Muotri, A. R. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391924-3.00028-4 · Cited by 1
Regulation of Autophagy in Health and Disease
Arachiche, A., & Gözüaçık, D. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13939-5_1 · Cited by 2
Modulation of Calcium Homeostasis by the Endoplasmic Reticulum in Health and Disease
Szabadkai, G., Chami, M., Pinton, P., & Rizzuto, R. (2003) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-9258-1_11 · Cited by 1
Revisiting Alzheimer's Disease from a New Prospective: Can “Risk Factors” Play a Key Role?
Price, J. L., Rubin, E. H., & Morris, J. C. (2000) · Journal of Alzheimer s Disease · doi:10.3233/jad-2000-2208 · Cited by 3
Características neuropatológicas y moleculares de la enfermedad de Alzheimer
Rodrigo, J., Martínez, A., Fernández, A. P., Serrano, J., Bentura, M. L., Moreno, E., Aparicio, M., Martínez‐Murillo, R., & Regidor, J. (2007) · Revista Española de Geriatría y Gerontología · doi:10.1016/s0211-139x(07)73533-3 · Cited by 6
Reduction of Aβ42 in brains of transgenic APP swe mice by 2‐3‐chlorophenylaminophenylacetate
Cohen, M. P., & Shearman, C. W. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05201.x · Cited by 1
Evidence for an Infectious Etiology in Alzheimer’s Disease
Balin, B. J., Hammond, C. J., Scott, C., Appelt, D. M., & Hingley, S. T. (2011) · InTech eBooks · doi:10.5772/29247 · Cited by 1
“The genes code for transmembrane proteins including β-amyloid precursor protein, presenilin 1 and presenilin 2 (Scheuner et al., 1996).”
BackgroundCatabolism of amyloid-β peptide in brain parenchyma
Saido, T. C., & Iwata, N. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8225-5_30 · Cited by 1
The Role of α-Synuclein in Parkinson’s Disease: A Biophysical Analogy to Aβ and Alzheimer’s Disease
Lansbury, P. T. (2000) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-662-04056-0_1 · Cited by 2
Using an Amyloid Precursor Protein (APP) Reporter to Characterize α-Secretase
Roberts, S. B. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:191 · Cited by 1
The Molecular Mechanism of Amyloidosis in Alzheimer’s Disease
Zagorski, M. G. (1999) · CRC Press eBooks · doi:10.1201/9780203909607.ch14 · Cited by 2
Alzheimer’s Disease and Mechanism-Based Attempts to Enhance Cognition
Draffin, J. E., Knafo, S., & Heneka, M. T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417042-1.00009-7 · Cited by 1
Cell-Based Alzheimer’s Disease Biomarkers
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00007-9 · Cited by 2
Usery, S. E. (2014) · IRL - University of Missouri, St. Louis (University of Missouri–St. Louis) · Cited by 1
Stover, K. R. (2012) · Library and Archives Canada (Government of Canada) · Cited by 2
Tau Phosphorylation and Amyloid-β Deposition in the Presence of Formaldehyde
Lü, J., & He, R. (2017) · Springer eBooks · doi:10.1007/978-94-024-1177-5_9 · Cited by 4
Genetics, Alzheimer’s disease and Down syndrome
Schupf, N. (2018) · CRC Press eBooks · doi:10.1201/9781315376875-3 · Cited by 1
Wolfe, M. S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382219-2.00066-1 · Cited by 1
Dementia of the Alzheimer type: current state of the problem
Tyuvina, N. A., & Владимировна, Б. В. (2014) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2014-1-61-67 · Cited by 1
Physiologic and Neurotoxic Properties of Aβ Peptides
Gregory, G. C., Shepherd, C. E., & Halliday, G. M. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_11 · Cited by 1
“Subsequent studies revealed that these genetic mutations increase the amount of the Aβ42 alloform over other Aβ species [14–16].”
BackgroundIkezu, T. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_30 · Cited by 2
Role of Liver in Alzheimer’s Disease
(2020) · ARC Journal of Neuroscience · doi:10.20431/2456-057x.0403003 · Cited by 1
EVALUATION OF THE PHYSIOLOGICAL FUNCTIONS OF BLEOMYCIN HYDROLASE IN THE MURINE CNS
Montoya, S. E. (2004) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Planchard, M. S. (2012) · Aquila Digital Community (University of Southern Mississippi) · Cited by 1
Solomon, B., Arbel‐Ornath, M., Peters-Libeu, C. A., & John, V. (2010) · Wiley eBooks · doi:10.1002/9780470594087.ch10 · Cited by 1
Biomarkers and Alzheimer spectrum
Takeda, M. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02197.x · Cited by 1
Alzheimer's Disease: Search for Therapeutics
Rzeszotarski, W. J. (2003) · Wiley eBooks · doi:10.1002/0471266949.bmc106 · Cited by 1
Lessons in familial Alzheimer’s disease
Rossor, M. N., Janssen, J. C., Fox, N. C., Harvey, R. J., Stevens, J., & Warrington, E. K. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8225-5_31 · Cited by 1
Intracellular Amyloid β: A Modification to the Amyloid Hypothesis in Alzheimer's Disease
Zhang, Y. (2011) · Wiley eBooks · doi:10.1002/9783527634323.ch6 · Cited by 1
Hamblett, C. L., Shah, S., Heidebrecht, R. W., & Muñoz, B. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527630943.ch13 · Cited by 1
Bothschafter, S. (2005) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.4110 · Cited by 4
Acylphosphatase Levels In Alzheimer’s Disease Cultured Skin Fibroblasts
Latorraca, S., Cecchi, C., Pieri, A., Liguri, G., Amaducci, L. A., & Sorbi, S. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_112 · Cited by 1
Chapter 1 Genetic Contributions to the Pathogenesis of Alzheimer's Disease
Mattson, M. P. (1999) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(08)60021-8 · Cited by 2
Treatment of Alzheimer's disease:
Shimohama, S. (2008) · Folia Pharmacologica Japonica · doi:10.1254/fpj.131.351 · Cited by 1
The aging synapse: Synaptic proteome changes in mouse models of aging
Végh, M. J. (2012) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) · Cited by 1
Weiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Issazadeh, S., Hancock, W. W., & Selkoe, D. J. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200010)48:4<567::aid-ana3>3.0.co;2-w · Cited by 263
Neuronal Regulation of Presenilin-1 Processing
Hartmann, H., Busciglio, J. A., & Yankner, B. A. (1998) · Springer eBooks · doi:10.1007/978-3-642-72103-8_10 · Cited by 1
Sugihara, S., Saunders, A. M., Ogawa, A., Nakazato, Y., Saido, T. C., & Yamaguchi, H. (1997) · Neuropathology · doi:10.1111/j.1440-1789.1997.tb00061.x · Cited by 1
Westaway, D. A., Carlson, G. A., Bergeron, C., Lévesque, G., Sherrington, R., Yao, H., Strome, R., Perry, B. J., Davies, A., Gandy, S., et al. (1998) · Springer eBooks · doi:10.1007/978-1-4899-1896-3_17 · Cited by 1
“However, fibroblasts from heterozygous carriers of PSI and PS2 mutations secrete increased levels of the amyloidogenic long-tailed amyloid ~-peptides ending at residues 42 or 43 (A~42)(Martin 1995)(Scheuner et al. 1996).”
BackgroundYamamoto, Y., Sengo, M., Yasuda, M., & Maeda, K. (2001) · Psychogeriatrics · doi:10.1111/j.1479-8301.2001.tb00004.x · Cited by 1
Part V. Genetic advances and biological markers for alzheimer's disease
Galasko, D. (2000) · Disease-a-Month · doi:10.1016/s0011-5029(00)90006-3 · Cited by 1
Strategies for Alzheimer's Disease Diagnosis
Estrada, L. D., & Soto, C. A. (2009) · Springer eBooks · doi:10.1007/978-0-387-87995-6_18 · Cited by 1
Genetically Engineered Models of Human Age-Related Neurodegenerative Diseases
Vickers, J. C. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50027-5 · Cited by 1
Amyloid (Tace, Bace) and Presenilin Proteases Associated with Alzheimer’s Disease
Marks, N., & Berg, M. J. (2002) · Springer eBooks · doi:10.1007/0-306-46847-6_11 · Cited by 2
Drosophila Melanogaster as a Model Organism for Dementia
Giannakou, M. E., & Crowther, D. C. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_12 · Cited by 3
Moskovitz, J., & Bush, A. I. (2005) · Oxidative stress and disease · doi:10.1201/9781420026559.ch11 · Cited by 1
Presenilin-Based Transgenic Models of Alzheimer’s Dementia
Yoshiike, Y., & Takashima, A. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_21 · Cited by 1
Drug Targets, Target identification, Validation and Screening
Zavitz, K. H., Bartel, P. L., & Hobden, A. N. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00005-6 · Cited by 1
Single Molecule Force Spectroscopy Investigations of Amyloid-β Aggregation
Hane, F. T. (2013) · UWSpace (University of Waterloo) · Cited by 2
Efficacy of Multifunctionalized Saccharide Constructs for the Attenuation of Amyloid-beta Toxicity
Dhavale, D. D. (2012) · Louisiana State University · doi:10.31390/gradschool_dissertations.2446 · Cited by 1
Beaton, D., Rieck, J. R., Alhazmi, F. H., ADNI, & Abdi, H. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/235945 · Cited by 1
“Interestingly and somewhat contrary to our expectations the “APOE-GWAS” did not detect any genotypes specifically associated with APP—a well-known causal factor to some forms of AD [81,82]—rather, effects of APP were”
ResultA non-human primate model of familial Alzheimer’s disease for translational medicinePreprint
Sato, K., Sasaguri, H., Kumita, W., Kurotani, Y., Inoue, T., Nagata, K., Mihira, N., Sato, K., Sakuma, T., Yamamoto, T., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-265068/v1 · Cited by 1
Zhao, M., Liu, J., He, J., Chen, X., Feng, Y., Wang, C., Liu, W., Liu, X., Liu, M., & Hou, D. (2021) · Research Square · doi:10.21203/rs.3.rs-750372/v1 · Cited by 1
Metabolic Abnormalities in Alzheimer Disease
Gebhardt, F. M., & Dodd, P. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-79112-8_22 · Cited by 2
Arbez, N. (2005) · HAL · Cited by 2
Klein, H., Kasper, S. F., Linden, M., Zaudig, M., Trautmann-Sponsel, R. D., Eikelmann, B., Zacharias, B., Wiedemann, G., Buchkremer, G., Laux, G., et al. (2003) · Springer eBooks · doi:10.1007/978-3-662-12451-2_14 · Cited by 1
Wang, J., Hecimovic, S. K., & Goate, A. (2006) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200300078 · Cited by 1
Swerdlow, R. H., Anderson, H. S., & Burns, J. M. (2010) · Springer eBooks · doi:10.1007/978-0-387-79948-3_290 · Cited by 1
Alzheimer's Disease, Familial, Early Onset
Teruel, B. M. (2004) · Informa Healthcare eBooks · doi:10.3109/9780203997352.011 · Cited by 1
Graff‐Radford, N. R. (2005) · Research and perspectives in Alzheimer's disease · doi:10.1007/3-540-26522-8_8 · Cited by 1
Qi, W., Long, Y., Li, Z., Zhao, Z., Shi, J., Xie, W., Wang, L., Tan, Y., Zhou, T., Jiang, P., et al. (2024) · eLife · doi:10.7554/elife.99462.1 · Cited by 1
Bezine, M. (2017) · theses.fr (ABES) · doi:10.70675/a634c389z7b07z4830zb56dzbf7b53a56944 · Cited by 1
Activated Neuroglia in Alzheimer's Disease
Brunden, K. R., & Frederickson, R. C. A. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-105-3_20 · Cited by 1
Early Onset Familial Alzheimer's Disease: Is a Mutation Predictive of Pathology?
Galasko, D. R. (2005) · Research and perspectives in Alzheimer's disease · doi:10.1007/3-540-26522-8_5 · Cited by 1
E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles
Lendon, C. L., Martinez, A., Behrens, I. M., Kosik, K. S., Madrigal, L., Norton, J., Neuman, R., Myers, A., Busfield, F., Wragg, M., et al. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)10:3
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Regulation of neuritogenesis in neuroblastoma cells by components of the WNT signalling pathway.
Orme, M. H. (2002) · OpenGrey (Institut de l'Information Scientifique et Technique)
Role of presenilin in APP processing and Aβ production
Xia, W., & Selkoe, D. J. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8225-5_21
Self-citationPresenilin und β-Amyloid: Schlüsselmoleküle der Alzheimerschen Erkrankung
Haass, C. (1998) · Springer eBooks · doi:10.1007/978-3-7091-6472-3_3
Hepburn, J. D. (2012) · Scholarship@Western (Western University)
Amyloid β-protein accumulation in the human brain during aging
Morishima‐Kawashima, M., & Ihara, Y. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8225-5_28
Biomolecular studies in Alzheimer’s Disease models: investigations in vitro and in vivo
Lattanzio, F. (2013) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/5507
“It has been demonstrated that the familial AD (FAD) - linked mutations of PSEN1, PSEN2 and APP causes AD by increasing the extracellular concentrations of Aβ42, thereby promoting its deposition on diffuse plaques in the earliest stage of the disease (Iwatsubo et al., 1994; Scheuner et al., 1996).”
BackgroundMolecular Genetics and Molecular Biology of Alzheimer’s Disease
Sandbrink, R., & Beyreuther, K. T. (2001) · Springer eBooks · doi:10.1007/978-3-642-59519-6_72
Strooper, B. D., Herreman, A., Cupers, P., Craessaerts, K., Serneels, L., & Annaert, W. G. (2001) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-662-04399-8_9
Molecular mechanisms underlying initiation of amyloid fibril formation
Yanagisawa, K. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8225-5_29
Gandy, S. (2002) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-06274-6_15
Peering into proteolysis with presenilins
Wolozin, B. L. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3204
Schieb, H. (2011) · DuEPublico (University of Duisburg-Essen)
Pasinetti, G. M. (2011) · Wiley eBooks · doi:10.1002/9781118148143.ch16
Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease
Golde, T. E. (2007) · Blue books of neurology · doi:10.1016/s1877-184x(09)70052-8
Structure/function studies of the alpha-crystallin small heat-shock chaperone proteins
Treweek, T. M. (2003) · Research Online (University of Wollongong)
Thinking Outside the Box in Alzheimer Disease Treatment
Castellani, R. J., Marlatt, M. W., Nunomura, A., Moreira, P. I., Lee, H., Casadesús, G., Zhu, X., Perry, G. L., & Smith, M. A. (2011) · Wiley eBooks · doi:10.1002/9780470571224.pse457
Thinakaran, G., Saura, C. A., Tomita, T., Honda, T., & Iwatsubo, T. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8225-5_19
Alzheimer disease : Studies on Abeta and gamma-secretase in human brain
Welander, H. (2009) · Figshare · Cited by 2
Johansson, S. M. (2005) · Figshare · Cited by 1
Cytotoxic properties of amyloidogenic L68Q cystatin C. A search for therapeutic agents
Ingólfsdóttir, I. E. (2013)
Gold nanoparticles and peptoids as novel inhibitors of Abeta aggregation in Alzheimer's disease
Moore, K. A. (2013) · Scholar Commons (University of South Carolina) · Cited by 2
INCREASED OXIDATIVE DAMAGE TO DNA AND THE EFFECTS ON MITOCHONDRIAL PROTEIN IN ALZHEIMER'S DISEASE
Wang, J. (2006) · UKnowledge (University of Kentucky) · Cited by 1
Etude de la régulation de deux protéines kinases : GSK-3 et polo
Primot, A. (2001) · HAL
Metabolism and Function of Presenilin 1
Sisodia, S. S., Thinakaran, G., Wong, P. C., Borchelt, D., Lee, M. K., Doan, A., Regard, J. B., Chen, H., Zheng, H., Eckman, C., et al. (1998) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-72103-8_5
Self-citationTransgenic Mice Model in Alzheimer's Disease
Duan, X., & Y., G. (2002) · Hong Kong journal of psychiatry · Cited by 1
Multilingualism and the risk of Alzheimer disease and dementia
Hack, E. E. (2011) · UWSpace (University of Waterloo)
Cracchiolo, J. R. (2005) · Digital Commons - University of South Florida (University of South Florida)
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.